

**Amendments to the Claims**

The following listing of claims replaces all prior versions of claims in the application:

1-50. Cancelled.

51 (new). A pharmaceutical composition comprising a sulfonate salt of paroxetine, calcium hydrogen phosphate anhydrate, a disintegrant and a lubricant; wherein said composition does not contain lactose or microcrystalline cellulose.

52 (new). The composition according to claim 51, wherein said composition does not contain a hydrosoluble or hydrophilic diluent.

53 (new). The composition according to claim 51, wherein said composition contains said calcium hydrogen phosphate anhydrate as the only diluent.

54 (new). The composition according to claim 51, wherein said sulfonate salt is paroxetine methane sulfonate.

55 (new). The composition according to claim 51, which consists essentially of paroxetine methane sulfonate, calcium hydrogen phosphate anhydrate, sodium starch glycolate, and magnesium stearate.

56 (new). A pharmaceutical composition comprising a sulfonate salt of paroxetine, calcium hydrogen phosphate anhydrate, a disintegrant and a lubricant; wherein said composition has a pH within the range of 5.0 to 6.0 and said composition has an added water content of 1.2 wt%.

57 (new). The pharmaceutical composition according to claim 56, which has an added water content of 0 to 1.0 wt%.

58 (new). The composition according to claim 56, which has an added water content of 0 to 0.8 wt%.

Divisional of Serial No. 09/939,561

59 (new). The composition according to claim 56, wherein said sulfonate salt is paroxetine methane sulfonate.